Literature DB >> 26268434

Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.

Yuan-qiang Zheng1, Youssef W Naguib, Yixuan Dong, Yan-chun Shi, Shorgan Bou, Zhengrong Cui.   

Abstract

Bacillus Calmette-Guerin (BCG) vaccines are attenuated live strains of Mycobacterium bovis and are among the most widely used vaccines in the world. BCG is proven to be effective in preventing severe infant meningitis and miliary tuberculosis. Intravesical instillation of BCG is also a standard treatment for non-muscle invasive bladder cancer. In the past few decades, recombinant BCG (rBCG) technology had been extensively applied to develop vaccine candidates for a variety of infectious diseases, including bacterial, viral, and parasite infections, and to improve the efficacy of BCG in bladder cancer therapy. This review is intended to show the vast applications of BCG and recombinant BCG (rBCG) in the prevention of infectious diseases and cancer immunotherapy, with a special emphasis on recent approaches and trends on both pre-clinical and clinical levels.

Entities:  

Keywords:  Bacillus Calmette-Guerin; bacterial vector; bladder cancer; clinical applications; infectious disease; recombinant BCG; tumor; vaccine development

Mesh：

Substances：

Year:  2015        PMID： 26268434      PMCID： PMC4920355     

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  204 in total

1.  Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.

Authors:  L R Kavoussi; E J Brown; J K Ritchey; T L Ratliff
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

2.  Adjuvant immunotherapy with B.C.G. in carcinoma of the prostate.

Authors:  M R Robinson; C C Rigby; R C Pugh; D C Dumonde
Journal:  Br J Urol       Date:  1977-06

3.  Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children.

Authors:  A C Hesseling; H Rabie; B J Marais; M Manders; M Lips; H S Schaaf; R P Gie; M F Cotton; P D van Helden; R M Warren; N Beyers
Journal:  Clin Infect Dis       Date:  2006-01-11       Impact factor: 9.079

Review 4.  Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree.

Authors:  T Oettinger; M Jørgensen; A Ladefoged; K Hasløv; P Andersen
Journal:  Tuber Lung Dis       Date:  1999

5.  Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro.

Authors:  Wujiang Liu; Michael A O'Donnell; Xiaohong Chen; Ruifa Han; Yi Luo
Journal:  Cancer Immunol Immunother       Date:  2009-02-13       Impact factor: 6.968

Review 6.  Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence.

Authors:  Behfar Ehdaie; Richard Sylvester; Harry W Herr
Journal:  Eur Urol       Date:  2013-05-18       Impact factor: 20.096

7.  Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.

Authors:  Riikka Järvinen; Eero Kaasinen; Anna Sankila; Erkki Rintala
Journal:  Eur Urol       Date:  2009-04-16       Impact factor: 20.096

8.  A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.

Authors:  S-H Wei; W Yin; Q-X An; Y-F Lei; X-B Hu; J Yang; X Lu; H Zhang; Z-K Xu
Journal:  Arch Virol       Date:  2008-04-18       Impact factor: 2.574

9.  Eimeria maxima: efficacy of recombinant Mycobacterium bovis BCG expressing apical membrane antigen1 against homologous infection.

Authors:  Wen-Chao Li; Xu-ke Zhang; Ling Du; Le Pan; Peng-Tao Gong; Jian-Hua Li; Ju Yang; He Li; Xi-Chen Zhang
Journal:  Parasitol Res       Date:  2013-08-15       Impact factor: 2.289

10.  Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.

Authors:  Rosamund Chapman; Enid Shephard; Helen Stutz; Nicola Douglass; Vasan Sambandamurthy; Irene Garcia; Bernhard Ryffel; William Jacobs; Anna-Lise Williamson
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240
View more
  19 in total

Review 1.  The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

Authors:  Ying Zhou; Peter J Little; Liam Downey; Rizwana Afroz; Yuao Wu; Hang T Ta; Suowen Xu; Danielle Kamato
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-06

2.  Immunogenicity and protective efficacy of recombinant Bacille Calmette-Guerin strains expressing mycobacterium antigens Ag85A, CFP10, ESAT-6, GM-CSF and IL-12p70.

Authors:  Fu-Ying Dai; Jun-Fang Wang; Xue-Li Gong; Lang Bao
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

Review 3.  Novel molecules as the emerging trends in cancer treatment: an update.

Authors:  Priyanka Sekar; Raashmi Ravitchandirane; Sofia Khanam; Nethaji Muniraj; Ananda Vayaravel Cassinadane
Journal:  Med Oncol       Date:  2022-01-04       Impact factor: 3.064

4.  Vitamin B6 Antidepressant Effects Are Comparable to Common Antidepressant Drugs in Bacillus-Calmette-Guerin Induced Depression Model in Mice.

Authors:  Azadeh Mesripour; Shirin Golchin
Journal:  Iran J Psychiatry       Date:  2022-04

5.  Immunogenicity and Protective Efficacy of T-Cell Epitopes Derived From Potential Th1 Stimulatory Proteins of Leishmania (Leishmania) donovani.

Authors:  Sumit Joshi; Narendra Kumar Yadav; Keerti Rawat; Vikash Kumar; Rafat Ali; Amogh Anant Sahasrabuddhe; Mohammad Imran Siddiqi; Wahajul Haq; Shyam Sundar; Anuradha Dube
Journal:  Front Immunol       Date:  2019-02-28       Impact factor: 7.561

Review 6.  Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.

Authors:  Kuan-Wei Shih; Wei-Chieh Chen; Ching-Hsin Chang; Ting-En Tai; Jeng-Cheng Wu; Andy C Huang; Ming-Che Liu
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

Review 7.  An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.

Authors:  Hamid Motamedi; Marzie Mahdizade Ari; Shirin Dashtbin; Matin Fathollahi; Hadi Hossainpour; Amirhoushang Alvandi; Jale Moradi; Ramin Abiri
Journal:  Int Immunopharmacol       Date:  2021-05-06       Impact factor: 5.714

8.  HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.

Authors:  Tsungai Ivai Jongwe; Ros Chapman; Nicola Douglass; Shivan Chetty; Gerald Chege; Anna-Lise Williamson
Journal:  PLoS One       Date:  2016-07-18       Impact factor: 3.240

Review 9.  The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.

Authors:  Natalie E Nieuwenhuizen; Prasad S Kulkarni; Umesh Shaligram; Mark F Cotton; Cyrill A Rentsch; Bernd Eisele; Leander Grode; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

Review 10.  Next-Generation Vaccines Based on Bacille Calmette-Guérin.

Authors:  Natalie E Nieuwenhuizen; Stefan H E Kaufmann
Journal:  Front Immunol       Date:  2018-02-05       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.